Previous 10 | Next 10 |
CEL-SCI has cleared a significant hurdle that mandates cancer drugs in Europe comply with strict requirements for pediatric usage and clinical evidence CEL-SCI Corporation (NYSE American: CVM) today announced that the European Medicines Agency (EMA) Paediatric Committee granted CE...
2023-12-26 01:16:46 ET More on Cel-Sci CEL-SCI spikes as U.K. picks cancer drug, Multikine for review CEL-SCI climbs after ESMO data for lead asset Multikine Seeking Alpha’s Quant Rating on Cel-Sci For further details see: Cel-Sci GAAP EPS of -$0.73
2023-12-04 12:47:12 ET Gainers: Hawaiian Holdings ( HA ) +187% . EyePoint Pharmaceuticals ( EYPT ) +177% . SilverSun Technologies ( SSNT ) +176% . Alterity Therapeutics Ltd ( ATHE ) +122% . View ( VIEW ) +82% . enGene Holding...
2023-12-04 12:24:52 ET More on Cel-Sci CEL-SCI climbs after ESMO data for lead asset Multikine Seeking Alpha’s Quant Rating on Cel-Sci Historical earnings data for Cel-Sci Financial information for Cel-Sci For further details see: CEL-SCI s...
CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine* (Leukocyte Interleukin, Injection) to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck ...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM) , a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 2,490,000 shares of its common stock to a single investor at a public offering...
2023-11-16 08:49:36 ET More on Cel-Sci CEL-SCI climbs after ESMO data for lead asset Multikine Seeking Alpha’s Quant Rating on Cel-Sci For further details see: CEL-SCI announces pricing of $5M offering of common stock
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 2,490,000 shares of its common stock to a single investor at an offering price of $2.00 per share, for g...
View the letter: https://cel-sci.com/wp-content/uploads/2023/10/CEL-SCI_shareholder_letter_from_CEO_Oct2023.pdf CEL-SCI Corporation (NYSE American: CVM) today released a letter to shareholders from the Company’s CEO, Geert Kersten. The very comprehensive letter ...
2023-10-25 08:44:46 ET Losers: Sonnet BioTherapeutics Holdings ( SONN ) -35% announces pricing of $4.55 Million underwritten public offering . Alphatec Holdings ( ATEC ) -18% prices $150M stock offering at $10.50 per share. MAIA Biotechnology ( MAIA ...
News, Short Squeeze, Breakout and More Instantly...
Cel-Sci Corporation Company Name:
CVM Stock Symbol:
NYSE Market:
CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as in...
CEL-4000 may deliver safe and effective therapy for RA by rebalancing the inflammatory response, without weakening important immune defense mechanisms, risking infections or cancer, as current treatments may CEL-SCI Corporation (NYSE American: CVM) today announced the peer rev...
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2023, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: CEL-SCI identified the target head and neck cancer patient popul...